



This is a repository copy of *Redefining hypoglycemia in clinical trials: validation of definitions recently adopted by the American Diabetes Association/European Association for the study of diabetes*.

White Rose Research Online URL for this paper:
<https://eprints.whiterose.ac.uk/154319/>

Version: Supplemental Material

Article:

Heller, S.R. orcid.org/0000-0002-2425-9565, Buse, J.B., Ratner, R. et al. (5 more authors) (2020) Redefining hypoglycemia in clinical trials: validation of definitions recently adopted by the American Diabetes Association/European Association for the study of diabetes. *Diabetes Care*, 43 (2). pp. 398-404. ISSN 0149-5992

<https://doi.org/10.2337/dc18-2361>

© 2019 by the American Diabetes Association. This is an author-created, uncopyedited electronic version of an article accepted for publication in *Diabetes Care*. The American Diabetes Association (ADA), publisher of *Diabetes Care*, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of/has been published in *Diabetes Care* in print and online at <https://doi.org/10.2337/dc18-2361>.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Redefining hypoglycemia in clinical trials: validation of definitions recently adopted by American Diabetes Association/European Association for the Study of Diabetes

Supplementary appendix:

Contents

Table S1: SWITCH and DEVOTE trial summary	2
Table S2: Hypoglycemia definitions applied to the SWITCH and DEVOTE trial data	4
Figure S1: Non-severe hypoglycemic events (total and symptomatic) in the total treatment period of SWITCH 2 and 1 at different plasma glucose levels in a pooled randomized treatment dataset	5
Figure S2: Estimated rate ratios of non-severe hypoglycemic events (total and symptomatic; degludec versus glargine U100) in the total treatment period of SWITCH 2 and 1 at different plasma glucose levels	6
Figure S3: Hypoglycemic events in SWITCH 1 by treatment group	7
References	8

Table S1: SWITCH and DEVOTE trial summary

	SWITCH 1 and 2	DEVOTE
Trial design	Double-blind, randomized, two-period crossover, multicenter, treat-to-target clinical trials	Double-blind, randomized, active comparator, treat-to-target cardiovascular outcomes trial
Trial duration	Time dependent: 64-weeks <ul style="list-style-type: none"> Two treatment periods (32 weeks each) each consisting of a 16-week titration period (Weeks 1–16 and Weeks 33–48) and a 16-week maintenance period (Weeks 17–32 and Weeks 49–64) 	Event driven: Continue until at least 633 MACE had accrued
Comparators	Degludec versus glargine U100	Degludec versus glargine U100
Inclusion criteria	<p>SWITCH 1:</p> <ul style="list-style-type: none"> Type 1 diabetes HbA_{1c} levels of ≤10% BMI ≤45 kg/m² Basal–bolus regimen or continuous subcutaneous insulin infusion for ≥26 weeks <p>SWITCH 2:</p> <ul style="list-style-type: none"> Insulin-experienced patients with type 2 diabetes HbA_{1c} levels of ≤9.5% BMI ≤45 kg/m² Any basal insulin with or without OADs (any combination of metformin, dipeptidyl peptidase-4 inhibitor, α-glucosidase inhibitor, thiazolidinediones, and sodium glucose cotransporter-2 inhibitor) 	<ul style="list-style-type: none"> Type 2 diabetes Treated with ≥1 oral or injectable antihyperglycemic agent HbA_{1c} ≥7.0%, or with ≥20 units/day of basal insulin ≥1 co-existing cardiovascular or renal condition and were aged ≥50 years OR ≥1 of a list of pre-specified cardiovascular risk factors and were aged ≥60 years Patients were not excluded if they had experienced severe hypoglycemia prior to randomization

	<p>SWITCH 1 and 2: At least 1 of the following risk factors for hypoglycemia:</p> <ul style="list-style-type: none"> • ≥1 severe hypoglycemic events within the last year • Moderate chronic renal failure • Hypoglycemia symptom unawareness • Diabetes duration >15 years (SWITCH 1)/Insulin use >5 years (SWITCH 2) • Hypoglycemic event within the last 12 weeks 	
References	(1,2)	(3,4)

BMI, body mass index; MACE, major adverse cardiovascular event; OAD, oral antidiabetes drug.

Table S2: Hypoglycemia definitions applied to the SWITCH and DEVOTE trial data


Hypoglycemia definitions applied in this secondary analysis		SWITCH	DEVOTE	References
ADA 2005	Events confirmed by a PG of ≤ 3.9 mmol/L with symptoms	✓		5
Level 2	Events confirmed by a glucose of < 3.0 mmol/L	✓		6
Level 3	Events requiring third-party assistance (ADA)	✓ ^{a,b}	✓ ^{a,b}	6,7
Novo Nordisk	Events confirmed by a PG of < 3.1 mmol/L with symptoms or events that are severe, requiring third-party assistance (ADA)	✓ ^b		1,2

ADA, American Diabetes Association; PG, plasma glucose.

^aAdjudicated by a central, blinded, independent Event Adjudication Committee.

^bPre-specified definition.


Figure S1: Non-severe hypoglycemic events (total and symptomatic) in the total treatment period of SWITCH 2 and 1 at different plasma glucose levels in a pooled randomized treatment dataset



The event rates in the pooled randomized treatment dataset (degludec and glargine U100) are plotted at a given plasma glucose level or lower.

PYE, patient year of exposure.


Figure S2: Estimated rate ratios of non-severe hypoglycemic events (total and symptomatic; degludec versus glargine U100) in the total treatment period of SWITCH 2 and 1 at different plasma glucose levels



The solid lines represent the estimated rate ratio (degludec versus glargine U100) at different plasma glucose levels. The dashed lines represent the upper and lower 95% confidence intervals.

Glargine U100, insulin glargine 100 units/mL.

Figure S3: Hypoglycemic events in SWITCH 1 by treatment group



^aThe total trial duration was 64 weeks; this included 32 weeks' treatment with once-daily degludec or glargine U100 followed by crossover to glargine U100 or degludec, respectively, for a further 32 weeks. Each 32-week treatment period consisted of a 16-week titration period and a 16-week maintenance period.

^bPre-specified hypoglycemia definition as used during the original trial.

ADA 2005: plasma glucose ≤ 3.9 mmol/L with symptoms; IHSG Level 2: glucose < 3.0 mmol/L; IHSG Level 3: severe events requiring third-party assistance intervention independent of a defined glucose; Novo Nordisk: plasma glucose < 3.1 mmol/L with symptoms plus severe events.

Glargine U100, insulin glargine 100 units/mL.

References

1. Lane W, Bailey TS, Gerety G, *et al.* Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. *JAMA* 2017;318:33–44.
2. Wysham C, Bhargava A, Chaykin L, *et al.* Effect of Insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. *JAMA* 2017;318:45–56.
3. Marso SP, McGuire DK, Zinman B, *et al.* Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) – DEVOTE 1. *Am Heart J* 2016;179:175–183
4. Marso SP, McGuire DK, Zinman B, *et al.* Efficacy and safety of degludec versus glargine in type 2 diabetes. *N Engl J Med* 2017;377:723–732.
5. American Diabetes Association Workgroup on Hypoglycemia. *Diabetes Care* 2005;28:1245–1249.
6. International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2017;40:155–157.
7. Seaquist ER, Anderson J, Childs B, *et al.* Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. *Diabetes Care* 2013;36:1384–1395.